Final results of a phase II trial of weekly nab-paclitaxel with GM-CSF as chemoimmunotherapy for platinum-resistant epithelial ovarian cancer.

被引：0
|
作者：
Swensen, Ron E.
Goff, Barbara Ann
Childs, Jennifer
Higgins, Doreen
Gooley, Theodore
Fintak, Patricia A.
Buening, Barbara
Disis, Mary L.
机构：
[1] Loma Linda Univ, Loma Linda, CA 92350 USA
[2] Univ Washington, Dept Obstet & Gynecol, Seattle, WA 98195 USA
[3] Univ Washington, Tumor Vaccine Grp, Seattle, WA 98195 USA
[4] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA
[5] Univ Washington, Seattle, WA 98195 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5082
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Randomized Phase II Study of Bevacizumab with Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant/Refractory High-Grade Ovarian Cancer (NCI Trial)
    Alqaisi, Husam A.
    Cohn, David E.
    Chern, Jing-Yi
    Duska, Linda R.
    Jewell, Andrea
    Corr, Bradley R.
    Winer, Ira Seth
    Girda, Eugenia
    Crispens, Marta A.
    Dhani, Neesha C.
    Madariaga, Ainhoa
    Grant, Robert C.
    Malaguti, Matthew
    Lee, Crystal
    Bowering, Valerie
    Wong, Horace
    Poothullil, Andrew
    Speers, Vanessa
    Wang, Lisa
    Bedard, Philippe L.
    Brady, John C.
    Nixon, Andrew B.
    Chen, Li
    O'Connor, Claire
    Zamboni, William
    Mckee, Tawyna
    Moscow, Jeffrey A.
    Oza, Amit M.
    Lheureux, Stephanie
    CLINICAL CANCER RESEARCH, 2025, 31 (06) : 993 - 1001
  • [22] Combretastatin A-4 phosphate (CA4P) carboplatin and paclitaxel in patients with platinum-resistant ovarian cancer: Final phase II trial results
    Zweifel, M.
    Jayson, G.
    Reed, N.
    Osborne, R.
    Hassan, B.
    Shreeves, G.
    Poupard, L.
    Walicke, P. A.
    Balkissoon, J.
    Chaplin, D.
    Rustin, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [23] A phase II study of weekly paclitaxel in platinum and paclitaxel-resistant ovarian cancer patients
    Kaern, J
    Baekelandt, M
    Tropé, CH
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2002, 23 (05) : 383 - 389
  • [24] ROSELLA (GOG-3073, ENGOT-OV72/MITO): A PHASE 3 STUDY OF RELACORILANT plus NAB-PACLITAXEL VS. NAB-PACLITAXEL IN ADVANCED, PLATINUM-RESISTANT OVARIAN CANCER
    Lorusso, Domenica
    Bagameri, Andrea
    Bishop, Erin
    Chudecka-Glaz, Anita
    Devaux, Alix
    Gladieff, Laurence
    Gordinier, Mary E.
    Kim, Jae-Weon
    Korach, Jacob
    Mccollum, Michael E.
    Mileshkin, Linda
    Monk, Bradley J.
    Nicum, Shibani
    Nogueira-Rodrigues, Angelica
    Oaknin, Ana
    O'Malley, David
    Orlando, Mauro
    Dreiling, Lyndah
    Tudor, Iulia Cristina
    Olawaiye, Alexander B.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 : A411 - A412
  • [25] A phase II study of ENMD-2076 in platinum-resistant ovarian cancer.
    Matulonis, U.
    Tew, W. P.
    Matei, D.
    Behbakht, K.
    Fleming, G. F.
    Oza, A. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [26] Preliminary results of a phase II study of gemcitabine and epirubicin in platinum-resistant or refractory advanced ovarian cancer.
    Arcuri, C
    Sorio, R
    Caffo, O
    Scalone, S
    Griso, C
    Lucenti, A
    Valdurga, F
    Frisinghelli, M
    Arisi, E
    Galligioni, E
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 472S - 472S
  • [27] Randomized Phase II Trial of Seribantumab in Combination With Paclitaxel in Patients With Advanced Platinum-Resistant or - Refractory Ovarian Cancer
    Liu, Joyce F.
    Ray-Coquard, Isabelle
    Selle, Frederic
    Poveda, Andres M.
    Cibula, David
    Hirte, Hal
    Hilpert, Felix
    Raspagliesi, Francesco
    Gladieff, Laurence
    Harter, Philipp
    Siena, Salvatore
    del Campo, Josep Maria
    Tabah-Fisch, Isabelle
    Pearlberg, Joseph
    Moyo, Victor
    Riahi, Kaveh
    Nering, Rachel
    Kubasek, William
    Adiwijaya, Bambang
    Czibere, Akos
    Naumann, R. Wendel
    Coleman, Robert L.
    Vergote, Ignace
    MacBeath, Gavin
    Pujade-Lauraine, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (36) : 4345 - +
  • [28] PHASE 2 TRIAL OF WEEKLY PACLITAXEL WITH PEMBROLIZUMAB IN PLATINUM RESISTANT RECURRENT OVARIAN CANCER
    Wenham, R. M.
    McGuire, W.
    Fridley, B.
    Boulware, D.
    Apte, S.
    Chon, H.
    Shahzad, M.
    Secord, A.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2018, 28 : 20 - 20
  • [29] Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer
    Zweifel, M.
    Jayson, G. C.
    Reed, N. S.
    Osborne, R.
    Hassan, B.
    Ledermann, J.
    Shreeves, G.
    Poupard, L.
    Lu, S. -P.
    Balkissoon, J.
    Chaplin, D. J.
    Rustin, G. J. S.
    ANNALS OF ONCOLOGY, 2011, 22 (09) : 2036 - 2041
  • [30] A phase 1 study of the SYK inhibitor fostamatinib and weekly paclitaxel for recurrent platinum-resistant ovarian cancer
    Gaillard, Stephanie
    Wilkinson, Mary
    Martin, Lainie P.
    Deery, Amy
    Langsdale, Amanda
    Bayable, Asnakech
    Zahurak, Marianna
    Huang, Peng
    Armstrong, Deborah Kay
    Shih, Ie-Ming
    Wang, Tian-Li
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345